nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—muscle cancer	0.44	1	CtDrD
Pazopanib—KIT—muscle cancer	0.258	1	CbGaD
Pazopanib—UGT1A1—Etoposide—muscle cancer	0.0207	0.147	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—muscle cancer	0.0202	0.143	CbGbCtD
Pazopanib—ABCG2—Vincristine—muscle cancer	0.0124	0.0883	CbGbCtD
Pazopanib—ABCG2—Etoposide—muscle cancer	0.0114	0.081	CbGbCtD
Pazopanib—CYP1A2—Dacarbazine—muscle cancer	0.00961	0.0682	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—muscle cancer	0.00948	0.0673	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—muscle cancer	0.00777	0.0552	CbGbCtD
Pazopanib—ABCG2—Methotrexate—muscle cancer	0.00753	0.0535	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—muscle cancer	0.00728	0.0517	CbGbCtD
Pazopanib—CYP2C8—Etoposide—muscle cancer	0.00607	0.0431	CbGbCtD
Pazopanib—CYP1A2—Etoposide—muscle cancer	0.0047	0.0334	CbGbCtD
Pazopanib—ABCB1—Vincristine—muscle cancer	0.00448	0.0319	CbGbCtD
Pazopanib—ABCB1—Etoposide—muscle cancer	0.00411	0.0292	CbGbCtD
Pazopanib—ABCB1—Doxorubicin—muscle cancer	0.0028	0.0199	CbGbCtD
Pazopanib—ABCB1—Methotrexate—muscle cancer	0.00272	0.0193	CbGbCtD
Pazopanib—CYP3A4—Vincristine—muscle cancer	0.00269	0.0191	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—muscle cancer	0.00264	0.0188	CbGbCtD
Pazopanib—CYP3A4—Etoposide—muscle cancer	0.00246	0.0175	CbGbCtD
Pazopanib—FGFR3—appendage—muscle cancer	0.00186	0.0364	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—muscle cancer	0.00168	0.0119	CbGbCtD
Pazopanib—FGF1—appendage—muscle cancer	0.00129	0.0252	CbGeAlD
Pazopanib—KDR—hindlimb—muscle cancer	0.00111	0.0217	CbGeAlD
Pazopanib—KDR—appendage—muscle cancer	0.000952	0.0187	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—muscle cancer	0.000698	0.509	CbGdCrCtD
Pazopanib—FGFR3—embryo—muscle cancer	0.000616	0.0121	CbGeAlD
Pazopanib—TAOK1—renal system—muscle cancer	0.000592	0.0116	CbGeAlD
Pazopanib—MAP3K9—vagina—muscle cancer	0.000571	0.0112	CbGeAlD
Pazopanib—MAP3K9—head—muscle cancer	0.000527	0.0103	CbGeAlD
Pazopanib—MAP3K9—testis—muscle cancer	0.000509	0.00999	CbGeAlD
Pazopanib—SH2B3—cardiac atrium—muscle cancer	0.000499	0.00978	CbGeAlD
Pazopanib—ITK—bone marrow—muscle cancer	0.000492	0.00964	CbGeAlD
Pazopanib—FLT4—embryo—muscle cancer	0.000481	0.00943	CbGeAlD
Pazopanib—ITK—vagina—muscle cancer	0.000471	0.00923	CbGeAlD
Pazopanib—FGFR3—renal system—muscle cancer	0.000466	0.00914	CbGeAlD
Pazopanib—TAOK1—bone marrow—muscle cancer	0.000447	0.00877	CbGeAlD
Pazopanib—SH2B3—tendon—muscle cancer	0.000435	0.00853	CbGeAlD
Pazopanib—TAOK1—vagina—muscle cancer	0.000429	0.0084	CbGeAlD
Pazopanib—PI4KB—smooth muscle tissue—muscle cancer	0.000429	0.0084	CbGeAlD
Pazopanib—AURKC—tendon—muscle cancer	0.000428	0.00839	CbGeAlD
Pazopanib—FGF1—embryo—muscle cancer	0.000427	0.00837	CbGeAlD
Pazopanib—SH2B3—bone marrow—muscle cancer	0.000421	0.00826	CbGeAlD
Pazopanib—ITK—testis—muscle cancer	0.00042	0.00824	CbGeAlD
Pazopanib—RIOK2—cardiac atrium—muscle cancer	0.000418	0.00819	CbGeAlD
Pazopanib—PI4KB—renal system—muscle cancer	0.000413	0.00809	CbGeAlD
Pazopanib—SH2B3—vagina—muscle cancer	0.000404	0.00791	CbGeAlD
Pazopanib—FGFR2—embryo—muscle cancer	0.000403	0.00791	CbGeAlD
Pazopanib—TAOK1—head—muscle cancer	0.000396	0.00776	CbGeAlD
Pazopanib—TAOK1—testis—muscle cancer	0.000382	0.0075	CbGeAlD
Pazopanib—PLK4—bone marrow—muscle cancer	0.000379	0.00744	CbGeAlD
Pazopanib—FLT1—embryo—muscle cancer	0.000374	0.00733	CbGeAlD
Pazopanib—SH2B3—head—muscle cancer	0.000373	0.00731	CbGeAlD
Pazopanib—STK16—tendon—muscle cancer	0.00037	0.00725	CbGeAlD
Pazopanib—PI4KB—cardiac atrium—muscle cancer	0.000369	0.00724	CbGeAlD
Pazopanib—AURKC—head—muscle cancer	0.000367	0.00719	CbGeAlD
Pazopanib—RIOK2—tendon—muscle cancer	0.000364	0.00714	CbGeAlD
Pazopanib—SH2B3—testis—muscle cancer	0.00036	0.00706	CbGeAlD
Pazopanib—AURKC—testis—muscle cancer	0.000354	0.00695	CbGeAlD
Pazopanib—RIOK2—bone marrow—muscle cancer	0.000353	0.00691	CbGeAlD
Pazopanib—PDGFRA—embryo—muscle cancer	0.00035	0.00687	CbGeAlD
Pazopanib—STK16—vagina—muscle cancer	0.000343	0.00673	CbGeAlD
Pazopanib—RIOK2—vagina—muscle cancer	0.000338	0.00662	CbGeAlD
Pazopanib—PLK4—Idarubicin—Doxorubicin—muscle cancer	0.000337	0.246	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—muscle cancer	0.000337	0.246	CbGdCrCtD
Pazopanib—FGF1—smooth muscle tissue—muscle cancer	0.000336	0.00658	CbGeAlD
Pazopanib—STK36—tendon—muscle cancer	0.000327	0.00641	CbGeAlD
Pazopanib—PLK4—testis—muscle cancer	0.000324	0.00636	CbGeAlD
Pazopanib—PIP4K2C—cardiac atrium—muscle cancer	0.000324	0.00635	CbGeAlD
Pazopanib—FGF1—renal system—muscle cancer	0.000323	0.00634	CbGeAlD
Pazopanib—PI4KB—tendon—muscle cancer	0.000322	0.00631	CbGeAlD
Pazopanib—FGFR1—cardiac atrium—muscle cancer	0.000322	0.0063	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—muscle cancer	0.000317	0.00622	CbGeAlD
Pazopanib—STK16—head—muscle cancer	0.000317	0.00621	CbGeAlD
Pazopanib—KDR—embryo—muscle cancer	0.000316	0.00619	CbGeAlD
Pazopanib—LYN—head—muscle cancer	0.000314	0.00615	CbGeAlD
Pazopanib—FGFR3—head—muscle cancer	0.000312	0.00612	CbGeAlD
Pazopanib—RIOK2—head—muscle cancer	0.000312	0.00612	CbGeAlD
Pazopanib—PI4KB—bone marrow—muscle cancer	0.000312	0.00611	CbGeAlD
Pazopanib—MAP3K19—head—muscle cancer	0.000309	0.00606	CbGeAlD
Pazopanib—BMPR1B—head—muscle cancer	0.000309	0.00606	CbGeAlD
Pazopanib—CSF1R—embryo—muscle cancer	0.000308	0.00605	CbGeAlD
Pazopanib—STK16—testis—muscle cancer	0.000306	0.006	CbGeAlD
Pazopanib—FGFR2—renal system—muscle cancer	0.000305	0.00598	CbGeAlD
Pazopanib—STK36—vagina—muscle cancer	0.000303	0.00595	CbGeAlD
Pazopanib—FGFR3—testis—muscle cancer	0.000301	0.00591	CbGeAlD
Pazopanib—RIOK2—testis—muscle cancer	0.000301	0.00591	CbGeAlD
Pazopanib—PI4KB—vagina—muscle cancer	0.000299	0.00586	CbGeAlD
Pazopanib—BMPR1B—testis—muscle cancer	0.000298	0.00585	CbGeAlD
Pazopanib—MAP3K19—testis—muscle cancer	0.000298	0.00585	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—muscle cancer	0.000294	0.00576	CbGeAlD
Pazopanib—LIMK2—vagina—muscle cancer	0.000293	0.00575	CbGeAlD
Pazopanib—FGF1—cardiac atrium—muscle cancer	0.000289	0.00567	CbGeAlD
Pazopanib—FLT1—renal system—muscle cancer	0.000283	0.00555	CbGeAlD
Pazopanib—PIP4K2C—tendon—muscle cancer	0.000283	0.00554	CbGeAlD
Pazopanib—STK36—head—muscle cancer	0.00028	0.00549	CbGeAlD
Pazopanib—FGFR1—tendon—muscle cancer	0.00028	0.00549	CbGeAlD
Pazopanib—KIT—embryo—muscle cancer	0.00028	0.00549	CbGeAlD
Pazopanib—PI4KB—head—muscle cancer	0.000276	0.00541	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—muscle cancer	0.000275	0.0054	CbGeAlD
Pazopanib—FLT4—bone marrow—muscle cancer	0.000275	0.00539	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—muscle cancer	0.000274	0.00536	CbGeAlD
Pazopanib—PDGFRB—embryo—muscle cancer	0.000274	0.00536	CbGeAlD
Pazopanib—LIMK2—head—muscle cancer	0.000271	0.00531	CbGeAlD
Pazopanib—STK36—testis—muscle cancer	0.000271	0.00531	CbGeAlD
Pazopanib—STK10—renal system—muscle cancer	0.000268	0.00525	CbGeAlD
Pazopanib—TAOK3—renal system—muscle cancer	0.000267	0.00523	CbGeAlD
Pazopanib—PI4KB—testis—muscle cancer	0.000267	0.00523	CbGeAlD
Pazopanib—PDGFRA—renal system—muscle cancer	0.000265	0.0052	CbGeAlD
Pazopanib—PIP4K2C—vagina—muscle cancer	0.000262	0.00514	CbGeAlD
Pazopanib—LIMK2—testis—muscle cancer	0.000262	0.00513	CbGeAlD
Pazopanib—FGFR1—vagina—muscle cancer	0.00026	0.0051	CbGeAlD
Pazopanib—MAP3K2—bone marrow—muscle cancer	0.000259	0.00509	CbGeAlD
Pazopanib—FLT1—cardiac atrium—muscle cancer	0.000253	0.00497	CbGeAlD
Pazopanib—UGT1A1—renal system—muscle cancer	0.000253	0.00496	CbGeAlD
Pazopanib—EPHB6—cardiac atrium—muscle cancer	0.00025	0.00491	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—muscle cancer	0.000248	0.00487	CbGeAlD
Pazopanib—FLT4—head—muscle cancer	0.000243	0.00477	CbGeAlD
Pazopanib—LCK—bone marrow—muscle cancer	0.000243	0.00476	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—muscle cancer	0.000242	0.00475	CbGeAlD
Pazopanib—PIP4K2C—head—muscle cancer	0.000242	0.00475	CbGeAlD
Pazopanib—KDR—renal system—muscle cancer	0.000239	0.00469	CbGeAlD
Pazopanib—TAOK3—cardiac atrium—muscle cancer	0.000239	0.00468	CbGeAlD
Pazopanib—FLT4—testis—muscle cancer	0.000235	0.00461	CbGeAlD
Pazopanib—PIP4K2C—testis—muscle cancer	0.000234	0.00459	CbGeAlD
Pazopanib—LCK—vagina—muscle cancer	0.000233	0.00456	CbGeAlD
Pazopanib—FGFR1—testis—muscle cancer	0.000232	0.00455	CbGeAlD
Pazopanib—MAP3K2—head—muscle cancer	0.00023	0.0045	CbGeAlD
Pazopanib—MAP3K2—testis—muscle cancer	0.000222	0.00435	CbGeAlD
Pazopanib—FLT1—tendon—muscle cancer	0.000221	0.00433	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—muscle cancer	0.00022	0.00432	CbGeAlD
Pazopanib—EPHB6—tendon—muscle cancer	0.000218	0.00428	CbGeAlD
Pazopanib—FGF1—head—muscle cancer	0.000216	0.00424	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—muscle cancer	0.000215	0.00422	CbGeAlD
Pazopanib—KDR—cardiac atrium—muscle cancer	0.000214	0.0042	CbGeAlD
Pazopanib—MAP2K5—cardiac atrium—muscle cancer	0.000214	0.0042	CbGeAlD
Pazopanib—KIT—renal system—muscle cancer	0.000212	0.00416	CbGeAlD
Pazopanib—SLCO1B1—renal system—muscle cancer	0.00021	0.00413	CbGeAlD
Pazopanib—STK10—tendon—muscle cancer	0.000209	0.0041	CbGeAlD
Pazopanib—CSF1R—cardiac atrium—muscle cancer	0.000209	0.0041	CbGeAlD
Pazopanib—FGF1—testis—muscle cancer	0.000209	0.0041	CbGeAlD
Pazopanib—TAOK3—tendon—muscle cancer	0.000208	0.00408	CbGeAlD
Pazopanib—LCK—testis—muscle cancer	0.000208	0.00407	CbGeAlD
Pazopanib—PDGFRB—renal system—muscle cancer	0.000207	0.00406	CbGeAlD
Pazopanib—PDGFRA—tendon—muscle cancer	0.000207	0.00406	CbGeAlD
Pazopanib—FLT1—vagina—muscle cancer	0.000205	0.00402	CbGeAlD
Pazopanib—FGFR2—head—muscle cancer	0.000204	0.004	CbGeAlD
Pazopanib—EPHB6—vagina—muscle cancer	0.000203	0.00397	CbGeAlD
Pazopanib—STK10—bone marrow—muscle cancer	0.000203	0.00397	CbGeAlD
Pazopanib—TAOK3—bone marrow—muscle cancer	0.000202	0.00395	CbGeAlD
Pazopanib—FGFR2—testis—muscle cancer	0.000197	0.00387	CbGeAlD
Pazopanib—STK10—vagina—muscle cancer	0.000194	0.0038	CbGeAlD
Pazopanib—TAOK3—vagina—muscle cancer	0.000193	0.00379	CbGeAlD
Pazopanib—PDGFRA—vagina—muscle cancer	0.000192	0.00376	CbGeAlD
Pazopanib—FLT1—head—muscle cancer	0.000189	0.00371	CbGeAlD
Pazopanib—EPHB6—head—muscle cancer	0.000187	0.00367	CbGeAlD
Pazopanib—KDR—tendon—muscle cancer	0.000187	0.00366	CbGeAlD
Pazopanib—MAP2K5—tendon—muscle cancer	0.000187	0.00366	CbGeAlD
Pazopanib—PDGFRB—cardiac atrium—muscle cancer	0.000185	0.00363	CbGeAlD
Pazopanib—FLT1—testis—muscle cancer	0.000183	0.00359	CbGeAlD
Pazopanib—CSF1R—tendon—muscle cancer	0.000182	0.00357	CbGeAlD
Pazopanib—KDR—bone marrow—muscle cancer	0.000181	0.00355	CbGeAlD
Pazopanib—EPHB6—testis—muscle cancer	0.000181	0.00354	CbGeAlD
Pazopanib—STK10—head—muscle cancer	0.000179	0.00351	CbGeAlD
Pazopanib—TAOK3—head—muscle cancer	0.000179	0.0035	CbGeAlD
Pazopanib—PDGFRA—head—muscle cancer	0.000177	0.00348	CbGeAlD
Pazopanib—CSF1R—bone marrow—muscle cancer	0.000176	0.00346	CbGeAlD
Pazopanib—KDR—vagina—muscle cancer	0.000173	0.0034	CbGeAlD
Pazopanib—MAP2K5—vagina—muscle cancer	0.000173	0.0034	CbGeAlD
Pazopanib—STK10—testis—muscle cancer	0.000173	0.00339	CbGeAlD
Pazopanib—TAOK3—testis—muscle cancer	0.000172	0.00338	CbGeAlD
Pazopanib—PDGFRA—testis—muscle cancer	0.000171	0.00336	CbGeAlD
Pazopanib—CSF1R—vagina—muscle cancer	0.000169	0.00331	CbGeAlD
Pazopanib—PDGFRB—tendon—muscle cancer	0.000162	0.00317	CbGeAlD
Pazopanib—KIT—bone marrow—muscle cancer	0.00016	0.00314	CbGeAlD
Pazopanib—KDR—head—muscle cancer	0.00016	0.00314	CbGeAlD
Pazopanib—MAP2K5—head—muscle cancer	0.00016	0.00314	CbGeAlD
Pazopanib—PDGFRB—bone marrow—muscle cancer	0.000157	0.00307	CbGeAlD
Pazopanib—CSF1R—head—muscle cancer	0.000156	0.00306	CbGeAlD
Pazopanib—KDR—testis—muscle cancer	0.000155	0.00303	CbGeAlD
Pazopanib—MAP2K5—testis—muscle cancer	0.000155	0.00303	CbGeAlD
Pazopanib—KIT—vagina—muscle cancer	0.000154	0.00301	CbGeAlD
Pazopanib—CSF1R—testis—muscle cancer	0.000151	0.00296	CbGeAlD
Pazopanib—PDGFRB—vagina—muscle cancer	0.00015	0.00294	CbGeAlD
Pazopanib—KIT—head—muscle cancer	0.000142	0.00278	CbGeAlD
Pazopanib—PDGFRB—head—muscle cancer	0.000139	0.00272	CbGeAlD
Pazopanib—KIT—testis—muscle cancer	0.000137	0.00269	CbGeAlD
Pazopanib—PDGFRB—testis—muscle cancer	0.000134	0.00262	CbGeAlD
Pazopanib—CYP2C8—renal system—muscle cancer	0.00012	0.00235	CbGeAlD
Pazopanib—CYP1A2—renal system—muscle cancer	0.000112	0.0022	CbGeAlD
Pazopanib—Pulmonary embolism—Doxorubicin—muscle cancer	0.00011	0.00268	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Doxorubicin—muscle cancer	0.00011	0.00268	CcSEcCtD
Pazopanib—Hiccups—Doxorubicin—muscle cancer	0.00011	0.00268	CcSEcCtD
Pazopanib—Myalgia—Dactinomycin—muscle cancer	0.000109	0.00266	CcSEcCtD
Pazopanib—Melaena—Doxorubicin—muscle cancer	0.000107	0.00262	CcSEcCtD
Pazopanib—Hypoaesthesia—Etoposide—muscle cancer	0.000106	0.00258	CcSEcCtD
Pazopanib—Anaemia—Vincristine—muscle cancer	0.000106	0.00258	CcSEcCtD
Pazopanib—Urinary tract disorder—Etoposide—muscle cancer	0.000105	0.00257	CcSEcCtD
Pazopanib—Skin exfoliation—Doxorubicin—muscle cancer	0.000105	0.00256	CcSEcCtD
Pazopanib—Oedema—Dactinomycin—muscle cancer	0.000105	0.00255	CcSEcCtD
Pazopanib—Urethral disorder—Etoposide—muscle cancer	0.000104	0.00255	CcSEcCtD
Pazopanib—Infection—Dactinomycin—muscle cancer	0.000104	0.00253	CcSEcCtD
Pazopanib—Blood urea increased—Doxorubicin—muscle cancer	0.000104	0.00253	CcSEcCtD
Pazopanib—Hepatic failure—Methotrexate—muscle cancer	0.000103	0.0025	CcSEcCtD
Pazopanib—Leukopenia—Vincristine—muscle cancer	0.000102	0.0025	CcSEcCtD
Pazopanib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000102	0.0025	CcSEcCtD
Pazopanib—Anorexia—Dactinomycin—muscle cancer	9.96e-05	0.00243	CcSEcCtD
Pazopanib—Eye disorder—Etoposide—muscle cancer	9.95e-05	0.00243	CcSEcCtD
Pazopanib—Mouth ulceration—Doxorubicin—muscle cancer	9.94e-05	0.00243	CcSEcCtD
Pazopanib—Flushing—Etoposide—muscle cancer	9.88e-05	0.00241	CcSEcCtD
Pazopanib—Cardiac disorder—Etoposide—muscle cancer	9.88e-05	0.00241	CcSEcCtD
Pazopanib—Hypertension—Vincristine—muscle cancer	9.88e-05	0.00241	CcSEcCtD
Pazopanib—Myalgia—Vincristine—muscle cancer	9.74e-05	0.00238	CcSEcCtD
Pazopanib—Angiopathy—Etoposide—muscle cancer	9.66e-05	0.00236	CcSEcCtD
Pazopanib—Mediastinal disorder—Etoposide—muscle cancer	9.6e-05	0.00234	CcSEcCtD
Pazopanib—Chills—Etoposide—muscle cancer	9.55e-05	0.00233	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	9.52e-05	0.00232	CcSEcCtD
Pazopanib—Alopecia—Etoposide—muscle cancer	9.41e-05	0.0023	CcSEcCtD
Pazopanib—Lethargy—Methotrexate—muscle cancer	9.41e-05	0.0023	CcSEcCtD
Pazopanib—Cerebrovascular accident—Methotrexate—muscle cancer	9.41e-05	0.0023	CcSEcCtD
Pazopanib—Oedema—Vincristine—muscle cancer	9.34e-05	0.00228	CcSEcCtD
Pazopanib—Infection—Vincristine—muscle cancer	9.28e-05	0.00226	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	9.18e-05	0.00224	CcSEcCtD
Pazopanib—Nervous system disorder—Vincristine—muscle cancer	9.16e-05	0.00223	CcSEcCtD
Pazopanib—Thrombocytopenia—Vincristine—muscle cancer	9.14e-05	0.00223	CcSEcCtD
Pazopanib—Hepatic function abnormal—Doxorubicin—muscle cancer	9.13e-05	0.00223	CcSEcCtD
Pazopanib—Decreased appetite—Dactinomycin—muscle cancer	9.09e-05	0.00222	CcSEcCtD
Pazopanib—Dysgeusia—Etoposide—muscle cancer	9.08e-05	0.00221	CcSEcCtD
Pazopanib—Hyperhidrosis—Vincristine—muscle cancer	9.03e-05	0.0022	CcSEcCtD
Pazopanib—Fatigue—Dactinomycin—muscle cancer	9.01e-05	0.0022	CcSEcCtD
Pazopanib—Pain—Dactinomycin—muscle cancer	8.94e-05	0.00218	CcSEcCtD
Pazopanib—Muscle spasms—Etoposide—muscle cancer	8.91e-05	0.00217	CcSEcCtD
Pazopanib—Anorexia—Vincristine—muscle cancer	8.9e-05	0.00217	CcSEcCtD
Pazopanib—Hepatic failure—Doxorubicin—muscle cancer	8.88e-05	0.00217	CcSEcCtD
Pazopanib—Cardiac failure congestive—Doxorubicin—muscle cancer	8.8e-05	0.00215	CcSEcCtD
Pazopanib—ABCG2—bone marrow—muscle cancer	8.8e-05	0.00172	CbGeAlD
Pazopanib—CYP2C8—vagina—muscle cancer	8.67e-05	0.0017	CbGeAlD
Pazopanib—Anaemia—Etoposide—muscle cancer	8.57e-05	0.00209	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dactinomycin—muscle cancer	8.55e-05	0.00209	CcSEcCtD
Pazopanib—Hot flush—Doxorubicin—muscle cancer	8.53e-05	0.00208	CcSEcCtD
Pazopanib—Liver function test abnormal—Methotrexate—muscle cancer	8.51e-05	0.00208	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Vincristine—muscle cancer	8.51e-05	0.00208	CcSEcCtD
Pazopanib—Menopausal symptoms—Doxorubicin—muscle cancer	8.46e-05	0.00206	CcSEcCtD
Pazopanib—Insomnia—Vincristine—muscle cancer	8.45e-05	0.00206	CcSEcCtD
Pazopanib—ABCG2—vagina—muscle cancer	8.43e-05	0.00165	CbGeAlD
Pazopanib—Paraesthesia—Vincristine—muscle cancer	8.38e-05	0.00205	CcSEcCtD
Pazopanib—Breast disorder—Methotrexate—muscle cancer	8.33e-05	0.00203	CcSEcCtD
Pazopanib—Leukopenia—Etoposide—muscle cancer	8.3e-05	0.00202	CcSEcCtD
Pazopanib—Abdominal pain—Dactinomycin—muscle cancer	8.26e-05	0.00202	CcSEcCtD
Pazopanib—Cardiac failure—Doxorubicin—muscle cancer	8.18e-05	0.002	CcSEcCtD
Pazopanib—Loss of consciousness—Etoposide—muscle cancer	8.15e-05	0.00199	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—muscle cancer	8.15e-05	0.00199	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—muscle cancer	8.15e-05	0.00199	CcSEcCtD
Pazopanib—Decreased appetite—Vincristine—muscle cancer	8.12e-05	0.00198	CcSEcCtD
Pazopanib—CYP3A4—renal system—muscle cancer	8.11e-05	0.00159	CbGeAlD
Pazopanib—Cough—Etoposide—muscle cancer	8.09e-05	0.00197	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vincristine—muscle cancer	8.06e-05	0.00197	CcSEcCtD
Pazopanib—Fatigue—Vincristine—muscle cancer	8.05e-05	0.00196	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—muscle cancer	8.01e-05	0.00196	CcSEcCtD
Pazopanib—Hypertension—Etoposide—muscle cancer	8e-05	0.00195	CcSEcCtD
Pazopanib—Pain—Vincristine—muscle cancer	7.99e-05	0.00195	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	7.98e-05	0.00195	CcSEcCtD
Pazopanib—CYP2D6—renal system—muscle cancer	7.98e-05	0.00156	CbGeAlD
Pazopanib—Chest pain—Etoposide—muscle cancer	7.89e-05	0.00193	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	7.84e-05	0.00191	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—muscle cancer	7.81e-05	0.00191	CcSEcCtD
Pazopanib—CYP2C8—testis—muscle cancer	7.74e-05	0.00152	CbGeAlD
Pazopanib—Face oedema—Doxorubicin—muscle cancer	7.71e-05	0.00188	CcSEcCtD
Pazopanib—Gastrointestinal pain—Vincristine—muscle cancer	7.64e-05	0.00186	CcSEcCtD
Pazopanib—ABCB1—embryo—muscle cancer	7.58e-05	0.00149	CbGeAlD
Pazopanib—ABCG2—testis—muscle cancer	7.52e-05	0.00147	CbGeAlD
Pazopanib—Infection—Etoposide—muscle cancer	7.51e-05	0.00183	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—muscle cancer	7.5e-05	0.00183	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—muscle cancer	7.48e-05	0.00182	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—muscle cancer	7.45e-05	0.00182	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—muscle cancer	7.42e-05	0.00181	CcSEcCtD
Pazopanib—Thrombocytopenia—Etoposide—muscle cancer	7.41e-05	0.00181	CcSEcCtD
Pazopanib—Abdominal pain—Vincristine—muscle cancer	7.38e-05	0.0018	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—muscle cancer	7.37e-05	0.0018	CcSEcCtD
Pazopanib—Skin disorder—Etoposide—muscle cancer	7.35e-05	0.00179	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—muscle cancer	7.32e-05	0.00179	CcSEcCtD
Pazopanib—Hyperhidrosis—Etoposide—muscle cancer	7.31e-05	0.00178	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—muscle cancer	7.29e-05	0.00178	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—muscle cancer	7.27e-05	0.00177	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—muscle cancer	7.21e-05	0.00176	CcSEcCtD
Pazopanib—Anorexia—Etoposide—muscle cancer	7.21e-05	0.00176	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	7.19e-05	0.00175	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—muscle cancer	7.15e-05	0.00174	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—muscle cancer	7.14e-05	0.00174	CcSEcCtD
Pazopanib—Infestation—Methotrexate—muscle cancer	7.1e-05	0.00173	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—muscle cancer	7.1e-05	0.00173	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	7.04e-05	0.00172	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—muscle cancer	6.95e-05	0.00169	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—muscle cancer	6.92e-05	0.00169	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—muscle cancer	6.79e-05	0.00166	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—muscle cancer	6.77e-05	0.00165	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—muscle cancer	6.76e-05	0.00165	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—muscle cancer	6.74e-05	0.00165	CcSEcCtD
Pazopanib—Somnolence—Etoposide—muscle cancer	6.72e-05	0.00164	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—muscle cancer	6.72e-05	0.00164	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—muscle cancer	6.7e-05	0.00163	CcSEcCtD
Pazopanib—Asthenia—Vincristine—muscle cancer	6.7e-05	0.00163	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—muscle cancer	6.65e-05	0.00162	CcSEcCtD
Pazopanib—Rash—Dactinomycin—muscle cancer	6.59e-05	0.00161	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—muscle cancer	6.58e-05	0.0016	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—muscle cancer	6.53e-05	0.00159	CcSEcCtD
Pazopanib—Fatigue—Etoposide—muscle cancer	6.52e-05	0.00159	CcSEcCtD
Pazopanib—Pain—Etoposide—muscle cancer	6.47e-05	0.00158	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—muscle cancer	6.45e-05	0.00157	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—muscle cancer	6.41e-05	0.00156	CcSEcCtD
Pazopanib—Diarrhoea—Vincristine—muscle cancer	6.39e-05	0.00156	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—muscle cancer	6.38e-05	0.00156	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—muscle cancer	6.3e-05	0.00154	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—muscle cancer	6.3e-05	0.00154	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—muscle cancer	6.25e-05	0.00153	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—muscle cancer	6.24e-05	0.00152	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—muscle cancer	6.21e-05	0.00151	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—muscle cancer	6.19e-05	0.00151	CcSEcCtD
Pazopanib—Dizziness—Vincristine—muscle cancer	6.17e-05	0.00151	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—muscle cancer	6.15e-05	0.0015	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—muscle cancer	6.15e-05	0.0015	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—muscle cancer	6e-05	0.00146	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—muscle cancer	6e-05	0.00146	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—muscle cancer	5.98e-05	0.00146	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—muscle cancer	5.96e-05	0.00145	CcSEcCtD
Pazopanib—Vomiting—Vincristine—muscle cancer	5.94e-05	0.00145	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—muscle cancer	5.92e-05	0.00144	CcSEcCtD
Pazopanib—Rash—Vincristine—muscle cancer	5.89e-05	0.00144	CcSEcCtD
Pazopanib—Dermatitis—Vincristine—muscle cancer	5.88e-05	0.00144	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—muscle cancer	5.87e-05	0.00143	CcSEcCtD
Pazopanib—Headache—Vincristine—muscle cancer	5.85e-05	0.00143	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—muscle cancer	5.82e-05	0.00142	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—muscle cancer	5.8e-05	0.00142	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—muscle cancer	5.79e-05	0.00141	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—muscle cancer	5.75e-05	0.0014	CcSEcCtD
Pazopanib—ABCB1—renal system—muscle cancer	5.74e-05	0.00112	CbGeAlD
Pazopanib—Chills—Methotrexate—muscle cancer	5.72e-05	0.0014	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—muscle cancer	5.64e-05	0.00137	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—muscle cancer	5.62e-05	0.00137	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—muscle cancer	5.59e-05	0.00136	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—muscle cancer	5.55e-05	0.00135	CcSEcCtD
Pazopanib—Erythema—Methotrexate—muscle cancer	5.55e-05	0.00135	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—muscle cancer	5.55e-05	0.00135	CcSEcCtD
Pazopanib—Nausea—Vincristine—muscle cancer	5.55e-05	0.00135	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—muscle cancer	5.52e-05	0.00135	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—muscle cancer	5.49e-05	0.00134	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—muscle cancer	5.45e-05	0.00133	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—muscle cancer	5.44e-05	0.00133	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—muscle cancer	5.44e-05	0.00133	CcSEcCtD
Pazopanib—Asthenia—Etoposide—muscle cancer	5.43e-05	0.00132	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—muscle cancer	5.43e-05	0.00132	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—muscle cancer	5.41e-05	0.00132	CcSEcCtD
Pazopanib—Pruritus—Etoposide—muscle cancer	5.35e-05	0.00131	CcSEcCtD
Pazopanib—CYP2D6—head—muscle cancer	5.34e-05	0.00105	CbGeAlD
Pazopanib—Vision blurred—Methotrexate—muscle cancer	5.23e-05	0.00128	CcSEcCtD
Pazopanib—Diarrhoea—Etoposide—muscle cancer	5.18e-05	0.00126	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—muscle cancer	5.16e-05	0.00126	CcSEcCtD
Pazopanib—CYP2D6—testis—muscle cancer	5.16e-05	0.00101	CbGeAlD
Pazopanib—Anaemia—Methotrexate—muscle cancer	5.13e-05	0.00125	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—muscle cancer	5.13e-05	0.00125	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—muscle cancer	5.13e-05	0.00125	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—muscle cancer	5.01e-05	0.00122	CcSEcCtD
Pazopanib—Dizziness—Etoposide—muscle cancer	5e-05	0.00122	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—muscle cancer	4.98e-05	0.00121	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—muscle cancer	4.97e-05	0.00121	CcSEcCtD
Pazopanib—Chills—Doxorubicin—muscle cancer	4.95e-05	0.00121	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—muscle cancer	4.88e-05	0.00119	CcSEcCtD
Pazopanib—Cough—Methotrexate—muscle cancer	4.84e-05	0.00118	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—muscle cancer	4.84e-05	0.00118	CcSEcCtD
Pazopanib—Vomiting—Etoposide—muscle cancer	4.81e-05	0.00117	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—muscle cancer	4.81e-05	0.00117	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—muscle cancer	4.81e-05	0.00117	CcSEcCtD
Pazopanib—Rash—Etoposide—muscle cancer	4.77e-05	0.00116	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—muscle cancer	4.77e-05	0.00116	CcSEcCtD
Pazopanib—Headache—Etoposide—muscle cancer	4.74e-05	0.00116	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—muscle cancer	4.74e-05	0.00116	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—muscle cancer	4.73e-05	0.00115	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—muscle cancer	4.73e-05	0.00115	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—muscle cancer	4.73e-05	0.00115	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—muscle cancer	4.71e-05	0.00115	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.69e-05	0.00115	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—muscle cancer	4.62e-05	0.00113	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—muscle cancer	4.53e-05	0.00111	CcSEcCtD
Pazopanib—Infection—Methotrexate—muscle cancer	4.5e-05	0.0011	CcSEcCtD
Pazopanib—Nausea—Etoposide—muscle cancer	4.49e-05	0.0011	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—muscle cancer	4.44e-05	0.00108	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—muscle cancer	4.44e-05	0.00108	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—muscle cancer	4.44e-05	0.00108	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—muscle cancer	4.4e-05	0.00107	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—muscle cancer	4.38e-05	0.00107	CcSEcCtD
Pazopanib—ABCB1—bone marrow—muscle cancer	4.34e-05	0.00085	CbGeAlD
Pazopanib—Anorexia—Methotrexate—muscle cancer	4.32e-05	0.00105	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—muscle cancer	4.31e-05	0.00105	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—muscle cancer	4.3e-05	0.00105	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—muscle cancer	4.23e-05	0.00103	CcSEcCtD
Pazopanib—Cough—Doxorubicin—muscle cancer	4.19e-05	0.00102	CcSEcCtD
Pazopanib—ABCB1—vagina—muscle cancer	4.16e-05	0.000815	CbGeAlD
Pazopanib—Hypertension—Doxorubicin—muscle cancer	4.15e-05	0.00101	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—muscle cancer	4.13e-05	0.00101	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—muscle cancer	4.1e-05	0.001	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—muscle cancer	4.09e-05	0.000999	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—muscle cancer	4.09e-05	0.000999	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—muscle cancer	4.09e-05	0.000999	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—muscle cancer	4.07e-05	0.000993	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4.06e-05	0.000992	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—muscle cancer	4.04e-05	0.000986	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—muscle cancer	4.03e-05	0.000983	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—muscle cancer	4e-05	0.000977	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—muscle cancer	3.99e-05	0.000973	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—muscle cancer	3.94e-05	0.000961	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—muscle cancer	3.92e-05	0.000957	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—muscle cancer	3.91e-05	0.000954	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—muscle cancer	3.91e-05	0.000953	CcSEcCtD
Pazopanib—Infection—Doxorubicin—muscle cancer	3.9e-05	0.000951	CcSEcCtD
Pazopanib—Pain—Methotrexate—muscle cancer	3.87e-05	0.000945	CcSEcCtD
Pazopanib—Shock—Doxorubicin—muscle cancer	3.86e-05	0.000942	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—muscle cancer	3.85e-05	0.000939	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—muscle cancer	3.84e-05	0.000937	CcSEcCtD
Pazopanib—ABCB1—head—muscle cancer	3.84e-05	0.000753	CbGeAlD
Pazopanib—Skin disorder—Doxorubicin—muscle cancer	3.81e-05	0.00093	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—muscle cancer	3.79e-05	0.000925	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—muscle cancer	3.74e-05	0.000912	CcSEcCtD
Pazopanib—ABCB1—testis—muscle cancer	3.71e-05	0.000727	CbGeAlD
Pazopanib—Gastrointestinal pain—Methotrexate—muscle cancer	3.71e-05	0.000904	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—muscle cancer	3.58e-05	0.000874	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.57e-05	0.000872	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—muscle cancer	3.55e-05	0.000866	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—muscle cancer	3.52e-05	0.00086	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—muscle cancer	3.5e-05	0.000853	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—muscle cancer	3.49e-05	0.000851	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—muscle cancer	3.45e-05	0.000843	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—muscle cancer	3.41e-05	0.000832	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.39e-05	0.000826	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—muscle cancer	3.38e-05	0.000825	CcSEcCtD
Pazopanib—Pain—Doxorubicin—muscle cancer	3.36e-05	0.000819	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—muscle cancer	3.25e-05	0.000793	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—muscle cancer	3.21e-05	0.000783	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—muscle cancer	3.21e-05	0.000782	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—muscle cancer	3.1e-05	0.000757	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—muscle cancer	3.1e-05	0.000756	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—muscle cancer	3e-05	0.000731	CcSEcCtD
Pazopanib—Vomiting—Methotrexate—muscle cancer	2.88e-05	0.000703	CcSEcCtD
Pazopanib—Rash—Methotrexate—muscle cancer	2.86e-05	0.000697	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—muscle cancer	2.85e-05	0.000696	CcSEcCtD
Pazopanib—Headache—Methotrexate—muscle cancer	2.84e-05	0.000693	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—muscle cancer	2.81e-05	0.000687	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—muscle cancer	2.78e-05	0.000677	CcSEcCtD
Pazopanib—Nausea—Methotrexate—muscle cancer	2.69e-05	0.000657	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—muscle cancer	2.68e-05	0.000655	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—muscle cancer	2.59e-05	0.000633	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—muscle cancer	2.49e-05	0.000609	CcSEcCtD
Pazopanib—Rash—Doxorubicin—muscle cancer	2.47e-05	0.000604	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—muscle cancer	2.47e-05	0.000603	CcSEcCtD
Pazopanib—Headache—Doxorubicin—muscle cancer	2.46e-05	0.0006	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—muscle cancer	2.33e-05	0.000569	CcSEcCtD
Pazopanib—FGFR3—Signaling Pathways—CNR1—muscle cancer	1.11e-05	0.000165	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—MDM2—muscle cancer	1.11e-05	0.000164	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—FOXO1—muscle cancer	1.1e-05	0.000162	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PTCH1—muscle cancer	1.1e-05	0.000162	CbGpPWpGaD
Pazopanib—KIT—Disease—FOXO4—muscle cancer	1.09e-05	0.000162	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—KIT—muscle cancer	1.09e-05	0.000161	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—KIT—muscle cancer	1.08e-05	0.000161	CbGpPWpGaD
Pazopanib—LCK—Signaling by NGF—MDM2—muscle cancer	1.08e-05	0.00016	CbGpPWpGaD
Pazopanib—FGF1—Immune System—FOXO1—muscle cancer	1.08e-05	0.000159	CbGpPWpGaD
Pazopanib—PLK4—Cell Cycle—TP53—muscle cancer	1.07e-05	0.000158	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—MDM2—muscle cancer	1.07e-05	0.000158	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—VEGFA—muscle cancer	1.06e-05	0.000157	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—KIT—muscle cancer	1.04e-05	0.000155	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—KIT—muscle cancer	1.04e-05	0.000154	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HMGA1—muscle cancer	1.04e-05	0.000154	CbGpPWpGaD
Pazopanib—FGFR1—Disease—FOXO4—muscle cancer	1.04e-05	0.000154	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—FOXO4—muscle cancer	1.04e-05	0.000153	CbGpPWpGaD
Pazopanib—FGFR1—Axon guidance—VEGFA—muscle cancer	1.03e-05	0.000153	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—FOXO1—muscle cancer	1.03e-05	0.000152	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—FOXO4—muscle cancer	1.01e-05	0.00015	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—FOXO4—muscle cancer	1.01e-05	0.00015	CbGpPWpGaD
Pazopanib—LCK—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.01e-05	0.00015	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—VEGFA—muscle cancer	1e-05	0.000148	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—CNR1—muscle cancer	9.95e-06	0.000147	CbGpPWpGaD
Pazopanib—FGF1—Disease—FOXO1—muscle cancer	9.94e-06	0.000147	CbGpPWpGaD
Pazopanib—LYN—Immune System—FOXO4—muscle cancer	9.89e-06	0.000147	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—FOXO4—muscle cancer	9.88e-06	0.000146	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—FOXO1—muscle cancer	9.88e-06	0.000146	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—KIT—muscle cancer	9.87e-06	0.000146	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—KIT—muscle cancer	9.76e-06	0.000145	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CNR1—muscle cancer	9.7e-06	0.000144	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—MDM2—muscle cancer	9.65e-06	0.000143	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—MED12—muscle cancer	9.63e-06	0.000143	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—KIT—muscle cancer	9.56e-06	0.000142	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—FOXO4—muscle cancer	9.43e-06	0.00014	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—KIT—muscle cancer	9.38e-06	0.000139	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—FOXO4—muscle cancer	9.33e-06	0.000138	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CNR1—muscle cancer	9.25e-06	0.000137	CbGpPWpGaD
Pazopanib—LCK—Disease—ENO2—muscle cancer	9.19e-06	0.000136	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—MDM2—muscle cancer	9.18e-06	0.000136	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—KIT—muscle cancer	9.18e-06	0.000136	CbGpPWpGaD
Pazopanib—FGFR3—Disease—KIT—muscle cancer	9.12e-06	0.000135	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IGF2—muscle cancer	9.1e-06	0.000135	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTCH1—muscle cancer	9.07e-06	0.000134	CbGpPWpGaD
Pazopanib—LYN—Axon guidance—VEGFA—muscle cancer	9.07e-06	0.000134	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—MDM2—muscle cancer	9.02e-06	0.000134	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—FH—muscle cancer	8.98e-06	0.000133	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—FOXO1—muscle cancer	8.91e-06	0.000132	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTCH1—muscle cancer	8.91e-06	0.000132	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—MED12—muscle cancer	8.83e-06	0.000131	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—MDM2—muscle cancer	8.82e-06	0.000131	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—MDM2—muscle cancer	8.82e-06	0.000131	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—ENO2—muscle cancer	8.78e-06	0.00013	CbGpPWpGaD
Pazopanib—KIT—Immune System—FOXO1—muscle cancer	8.75e-06	0.00013	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—MDM2—muscle cancer	8.66e-06	0.000128	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—MDM2—muscle cancer	8.56e-06	0.000127	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—MDM2—muscle cancer	8.54e-06	0.000126	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTCH1—muscle cancer	8.46e-06	0.000125	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTCH1—muscle cancer	8.43e-06	0.000125	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—FOXO1—muscle cancer	8.38e-06	0.000124	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—KIT—muscle cancer	8.36e-06	0.000124	CbGpPWpGaD
Pazopanib—LCK—Disease—HMGA1—muscle cancer	8.35e-06	0.000124	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—FOXO1—muscle cancer	8.31e-06	0.000123	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—FOXO1—muscle cancer	8.29e-06	0.000123	CbGpPWpGaD
Pazopanib—FGFR2—Disease—FOXO1—muscle cancer	8.23e-06	0.000122	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—MDM2—muscle cancer	8.22e-06	0.000122	CbGpPWpGaD
Pazopanib—FGF1—Immune System—KIT—muscle cancer	8.21e-06	0.000122	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—MDM2—muscle cancer	8.2e-06	0.000121	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—MED12—muscle cancer	8.17e-06	0.000121	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IGF2—muscle cancer	8.14e-06	0.000121	CbGpPWpGaD
Pazopanib—LCK—Immune System—FOXO4—muscle cancer	8.11e-06	0.00012	CbGpPWpGaD
Pazopanib—KIT—Disease—FOXO1—muscle cancer	8.08e-06	0.00012	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—ENO2—muscle cancer	8.05e-06	0.000119	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—TP53—muscle cancer	7.98e-06	0.000118	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IGF2—muscle cancer	7.93e-06	0.000117	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.92e-06	0.000117	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—KIT—muscle cancer	7.84e-06	0.000116	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.83e-06	0.000116	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—FH—muscle cancer	7.82e-06	0.000116	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—FOXO4—muscle cancer	7.8e-06	0.000116	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—MDM2—muscle cancer	7.78e-06	0.000115	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—MDM2—muscle cancer	7.69e-06	0.000114	CbGpPWpGaD
Pazopanib—FGFR1—Disease—FOXO1—muscle cancer	7.67e-06	0.000114	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—FOXO4—muscle cancer	7.66e-06	0.000113	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CNR1—muscle cancer	7.66e-06	0.000113	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—FOXO1—muscle cancer	7.65e-06	0.000113	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	7.6e-06	0.000113	CbGpPWpGaD
Pazopanib—FGF1—Disease—KIT—muscle cancer	7.58e-06	0.000112	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IGF2—muscle cancer	7.57e-06	0.000112	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	7.55e-06	0.000112	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—MDM2—muscle cancer	7.53e-06	0.000112	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KIT—muscle cancer	7.52e-06	0.000111	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CNR1—muscle cancer	7.52e-06	0.000111	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	7.49e-06	0.000111	CbGpPWpGaD
Pazopanib—LCK—Disease—FOXO4—muscle cancer	7.49e-06	0.000111	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—FOXO1—muscle cancer	7.46e-06	0.000111	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ENO2—muscle cancer	7.45e-06	0.00011	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTCH1—muscle cancer	7.44e-06	0.00011	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	7.38e-06	0.000109	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—FH—muscle cancer	7.37e-06	0.000109	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—VEGFA—muscle cancer	7.36e-06	0.000109	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—VEGFA—muscle cancer	7.32e-06	0.000108	CbGpPWpGaD
Pazopanib—LYN—Immune System—FOXO1—muscle cancer	7.31e-06	0.000108	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—FOXO1—muscle cancer	7.3e-06	0.000108	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—FOXO4—muscle cancer	7.27e-06	0.000108	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	7.25e-06	0.000107	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—MDM2—muscle cancer	7.23e-06	0.000107	CbGpPWpGaD
Pazopanib—FGFR3—Disease—MDM2—muscle cancer	7.18e-06	0.000106	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CNR1—muscle cancer	7.14e-06	0.000106	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	7.12e-06	0.000105	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—FOXO1—muscle cancer	6.96e-06	0.000103	CbGpPWpGaD
Pazopanib—FGFR3—Disease—PTGS2—muscle cancer	6.92e-06	0.000103	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—FOXO1—muscle cancer	6.89e-06	0.000102	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KIT—muscle cancer	6.79e-06	0.000101	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—VEGFA—muscle cancer	6.7e-06	9.92e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MDM2—muscle cancer	6.58e-06	9.75e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	6.53e-06	9.68e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—VEGFA—muscle cancer	6.47e-06	9.59e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—MDM2—muscle cancer	6.46e-06	9.57e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	6.41e-06	9.5e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—FOXO4—muscle cancer	6.4e-06	9.48e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KIT—muscle cancer	6.38e-06	9.45e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—VEGFA—muscle cancer	6.35e-06	9.41e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KIT—muscle cancer	6.33e-06	9.37e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KIT—muscle cancer	6.31e-06	9.35e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.29e-06	9.32e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CNR1—muscle cancer	6.28e-06	9.3e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KIT—muscle cancer	6.27e-06	9.29e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IGF2—muscle cancer	6.26e-06	9.27e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—FH—muscle cancer	6.24e-06	9.25e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—MDM2—muscle cancer	6.17e-06	9.14e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IGF2—muscle cancer	6.15e-06	9.11e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTCH1—muscle cancer	6.1e-06	9.03e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—FOXO1—muscle cancer	5.99e-06	8.87e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MDM2—muscle cancer	5.97e-06	8.84e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.94e-06	8.8e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—MDM2—muscle cancer	5.93e-06	8.78e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KIT—muscle cancer	5.84e-06	8.65e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IGF2—muscle cancer	5.84e-06	8.64e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KIT—muscle cancer	5.83e-06	8.63e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	5.82e-06	8.62e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—FOXO1—muscle cancer	5.76e-06	8.53e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PTGS2—muscle cancer	5.75e-06	8.52e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KIT—muscle cancer	5.71e-06	8.45e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KIT—muscle cancer	5.69e-06	8.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—FOXO1—muscle cancer	5.66e-06	8.38e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—KIT—muscle cancer	5.57e-06	8.25e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KIT—muscle cancer	5.56e-06	8.24e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—TP53—muscle cancer	5.53e-06	8.2e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—FOXO1—muscle cancer	5.53e-06	8.19e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—FOXO1—muscle cancer	5.37e-06	7.95e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	5.36e-06	7.93e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—MDM2—muscle cancer	5.35e-06	7.92e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KIT—muscle cancer	5.3e-06	7.86e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—MDM2—muscle cancer	5.25e-06	7.78e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KIT—muscle cancer	5.25e-06	7.78e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FOXO4—muscle cancer	5.24e-06	7.77e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	5.24e-06	7.77e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—VEGFA—muscle cancer	5.21e-06	7.71e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CNR1—muscle cancer	5.15e-06	7.62e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IGF2—muscle cancer	5.13e-06	7.6e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MED12—muscle cancer	5.07e-06	7.51e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—TP53—muscle cancer	5.06e-06	7.5e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MDM2—muscle cancer	5.03e-06	7.45e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—VEGFA—muscle cancer	5e-06	7.4e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—MDM2—muscle cancer	4.98e-06	7.38e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—MDM2—muscle cancer	4.97e-06	7.36e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MDM2—muscle cancer	4.94e-06	7.31e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MDM2—muscle cancer	4.85e-06	7.18e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	4.83e-06	7.15e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—FH—muscle cancer	4.82e-06	7.14e-05	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—TP53—muscle cancer	4.8e-06	7.11e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PTGS2—muscle cancer	4.76e-06	7.05e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—FOXO1—muscle cancer	4.72e-06	7e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PTGS2—muscle cancer	4.67e-06	6.92e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ENO2—muscle cancer	4.62e-06	6.85e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MDM2—muscle cancer	4.6e-06	6.82e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MDM2—muscle cancer	4.59e-06	6.8e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KIT—muscle cancer	4.56e-06	6.76e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	4.49e-06	6.66e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.49e-06	6.65e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—MDM2—muscle cancer	4.48e-06	6.63e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PTGS2—muscle cancer	4.44e-06	6.57e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PTGS2—muscle cancer	4.43e-06	6.55e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MED12—muscle cancer	4.42e-06	6.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KIT—muscle cancer	4.39e-06	6.5e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—MDM2—muscle cancer	4.39e-06	6.49e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MDM2—muscle cancer	4.38e-06	6.49e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KIT—muscle cancer	4.21e-06	6.24e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF2—muscle cancer	4.21e-06	6.23e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MDM2—muscle cancer	4.18e-06	6.19e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MED12—muscle cancer	4.16e-06	6.17e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MDM2—muscle cancer	4.14e-06	6.12e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KIT—muscle cancer	4.09e-06	6.06e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KIT—muscle cancer	4.08e-06	6.05e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO2—muscle cancer	4.03e-06	5.97e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PTGS2—muscle cancer	3.99e-06	5.9e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TP53—muscle cancer	3.93e-06	5.83e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FOXO1—muscle cancer	3.87e-06	5.74e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—VEGFA—muscle cancer	3.82e-06	5.65e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO2—muscle cancer	3.8e-06	5.62e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TP53—muscle cancer	3.78e-06	5.59e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KIT—muscle cancer	3.68e-06	5.45e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.62e-06	5.36e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KIT—muscle cancer	3.6e-06	5.33e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—MDM2—muscle cancer	3.59e-06	5.32e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MED12—muscle cancer	3.53e-06	5.23e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MDM2—muscle cancer	3.46e-06	5.12e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	3.41e-06	5.05e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MDM2—muscle cancer	3.4e-06	5.03e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—VEGFA—muscle cancer	3.33e-06	4.93e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MDM2—muscle cancer	3.32e-06	4.92e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MDM2—muscle cancer	3.22e-06	4.77e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO2—muscle cancer	3.22e-06	4.76e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	3.21e-06	4.76e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—muscle cancer	3.2e-06	4.74e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—muscle cancer	3.17e-06	4.7e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—muscle cancer	3.06e-06	4.53e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KIT—muscle cancer	2.95e-06	4.37e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	2.9e-06	4.29e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—muscle cancer	2.88e-06	4.27e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MDM2—muscle cancer	2.84e-06	4.2e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—muscle cancer	2.8e-06	4.15e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MED12—muscle cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—muscle cancer	2.63e-06	3.89e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—muscle cancer	2.6e-06	3.84e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—muscle cancer	2.58e-06	3.82e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—muscle cancer	2.58e-06	3.82e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.52e-06	3.73e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—muscle cancer	2.51e-06	3.72e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO2—muscle cancer	2.48e-06	3.68e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—muscle cancer	2.45e-06	3.62e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	2.44e-06	3.62e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—muscle cancer	2.4e-06	3.55e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—muscle cancer	2.32e-06	3.44e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	2.2e-06	3.26e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—muscle cancer	2.15e-06	3.19e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—muscle cancer	1.98e-06	2.94e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—muscle cancer	1.95e-06	2.89e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—muscle cancer	1.85e-06	2.74e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—muscle cancer	1.84e-06	2.73e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—muscle cancer	1.76e-06	2.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—muscle cancer	1.66e-06	2.46e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—muscle cancer	1.63e-06	2.41e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—muscle cancer	1.61e-06	2.39e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—muscle cancer	1.4e-06	2.08e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—muscle cancer	1.33e-06	1.97e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—muscle cancer	1.32e-06	1.96e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—muscle cancer	1.12e-06	1.66e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—muscle cancer	8.65e-07	1.28e-05	CbGpPWpGaD
